Shilpa Medicare bags CDSCO nod for topical hemostatic spray of Tranexamic Acid
The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038.
Hyderabad: Shilpa Medicare has announced that the company has received Central Drugs Standard Control Organisation (CDSCO) approval for the topical hemostatic spray of Tranexamic Acid.
This novel formulation of spray is simple, easy to carry, convenient to use and a lifesaving tool. It is Clinically proven in humans and validated in robust swine trauma model. The product is approved for the usage of reducing or preventing hemorrhage and to reduce the need of replacement therapy during accidental and domestic injury.
The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038.
"Shilpa is continuously pursuing patent prosecution in other countries and for further protection," the company stated in a BSE filing.
Read also: Shilpa Medicare Raichur facility gets Russian GMP certificate
Shilpa Medicare Limited started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India.
The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.
Read also: Shilpa Medicare gets USFDA nod for Tenofovir Alafenamide Tablets
